Status:
COMPLETED
Optical Coherence Tomography (OCT) and OCT Angiography(OCTA) Deep Learning in Waldenström's Macroglobulinemia Patients
Lead Sponsor:
Federico II University
Conditions:
Waldenstrom Macroglobulinemia
Eligibility:
All Genders
18-80 years
Brief Summary
This study evaluates the ability of deep learning to improve the knowledge about structural and vascular retinal changes in Waldenström's Macroglobulinemia patients, using optical coherence tomography...
Detailed Description
Waldenstrom macroglobulinemia (mak-roe-glob-u-lih-NEE-me-uh) is a rare type of cancer that begins in the white blood cells. The optical coherence tomography angiography represents a novel and noninva...
Eligibility Criteria
Inclusion
- age older than 18 years
- diagnosis of Waldenstrom Macroglobulinemia
- absence of previous ocular surgery and congenital eye diseases.
- absence of errors of refraction
- absence of lens opacities
- absence of low-quality OCT and OCTA images
Exclusion
- • age younger than 18 years
- previous ocular surgery and congenital eye diseases
- errors of refraction
- lens opacities
- low-quality OCT and OCTA images
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06084650
Start Date
January 1 2023
End Date
October 1 2023
Last Update
May 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Naples "Federico II" Naples, Italy, 80100 Contact: Gilda Cennamo, MD 00390817143731 xgilda@hotmail.com
Napoli, Italy